Persistence to Adjuvant Endocrine Therapy for Breast Cancer in Botswana: An Observational Cohort Analysis
Interruptions to adjuvant endocrine therapy in Botswana is common, but rates of persistence remain high. Medication stockout was the most common reasons for interruption of adjuvant endocrine therapy.
Authors
- Peter Vuylsteke (ORCID: https://orcid.org/0000-0001-6401-3722)
- Scott Dryden‐Peterson (ORCID: https://orcid.org/0000-0002-8487-9731)
- Elizabeth Y. Chiao (ORCID: https://orcid.org/0000-0001-5752-2916)
- James R. Wester (ORCID: https://orcid.org/0000-0002-9607-8982)
- Arthur T. Johnson (ORCID: https://orcid.org/0000-0002-4493-9285)
- Oaitse John
- Taolo Ntloedibe
- Jose Euberto Mendez Reyes (ORCID: https://orcid.org/0009-0000-5823-3358)
Institutions
- Brigham and Women's Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- University of Botswana (BW)
- Baylor College of Medicine (US)
- Hospital of the University of Pennsylvania (US)
- Botswana Harvard AIDS Institute Partnership (BW)
- Botswana-Baylor Children's Clinical Center of Excellence (BW)
Publication Details
- Journal
- Breast Care
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1159/000547028
- Citations
- 1
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.13